Dimerix (DXB) H2 2026 earnings summary

Executive summary

• Completed enrolment of the ACTION3 Phase 3 trial for DMX-200 in FSGS, with final adult patient dosed in March 2026 and >90% statistical power confirmed for efficacy endpoint.

• Secured a major licensing agreement with Everest Medicines for Greater China, South Korea, and Southeast Asia, increasing total potential licensing deal value to ~A$1.9 billion, with over A$81 million received to date.

• Expanded pipeline by acquiring DMX-652, a Phase 2-ready kidney disease asset, with US patent protection through at least 2043.

• Ended the year with A$16.2 million in cash reserves, not including the US$10 million Everest upfront payment received post year-end.

• Maintained disciplined cost management while prioritizing R&D and talent investment.

Financial highlights

• Revenue from ordinary activities was $4.35 million, primarily from license income amortized over the life of the licenses.

• Net loss after tax increased 125% year-over-year to $29.8 million (2025: $13.3 million), driven by higher R&D expenditure.

• R&D expenditure rose to $36.0 million (2025: $27.3 million), reflecting the scale of the Phase 3 trial.

• Cash and cash equivalents at year-end were $16.2 million (2025: $68.3 million).

• Net tangible assets per ordinary security declined to $(0.0633) from $(0.0093) in the prior year.

Outlook and guidance

• Focused on completing the ACTION3 Phase 3 trial and advancing toward regulatory approval and commercialization of DMX-200.

• Plans to initiate and advance Phase 2 clinical development for DMX-652.

• Intends to pursue additional regional licensing and non-dilutive funding to support pipeline expansion and late-stage development.